Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat versus salmeterol and placebo in moderate persistent asthma with ADRB2 Arg16 homozygosity
2005-005616-25Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Tiotropium Respimat, Salmeterol and Placebo (3 arms). Primary endpoint: Change in mean weekly morning peak expiratory flow from baseline to the last week of treatment. Started May 2006; status: completed.
02
Drugs
tiotropiumsalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2005-005616-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005616-25.